Investment Rating - The report maintains an "Outperform" rating for Sunny Optical Technology [2][10][17] Core Insights - Sunny Optical is expected to achieve attributable net profit of RMB 45.89–47.24 billion in 2025, representing a year-on-year increase of 70% to 75%, significantly above Bloomberg consensus of RMB 35.39 billion. This upside is primarily driven by a one-off investment gain of approximately RMB 9.19 billion from an equity transfer for a stake in Goertek Optics. Excluding this non-recurring item, the core attributable net profit is estimated to be RMB 36.7–38.05 billion, supported by the ongoing premiumization of smartphone camera specifications [3][13] - The company continues to benefit from the upgrade of camera specifications in flagship and mid-to-high-end smartphones, which is expected to enhance both average selling price (ASP) and gross margin for handset lenses and camera modules [4][14] Summary by Relevant Sections Handsets - Despite ongoing headwinds from rising memory costs, the trend of optical upgrades remains intact. The company is well-positioned to benefit from the adoption of higher-value products such as variable aperture and periscope cameras, which will drive ASP and margin expansion [4][14] Automotive - The adoption of intelligent driving technologies is expected to significantly boost the company's automotive lens and module businesses. The average number of cameras per vehicle is projected to increase, with high-end vehicles already equipped with around 12 cameras [5][15] XR & IoT - The company maintains its global leadership in imaging modules for smart glasses, with strong growth in revenue from handheld imaging devices. The rapid expansion of AI and AR glasses is anticipated to be a key growth driver in the coming years [6][16] Valuation - The estimated EPS for 2025-2027 is revised to RMB 4.23, 3.86, and 4.19 respectively. Based on a P/E ratio of 19.6x for 2026, the target price is set at HKD 85.24 [6][17]

Investment Rating - The report assigns a positive outlook on China Medical System Holdings, indicating a potential for significant revenue growth from the newly approved ruxolitinib cream [1][3]. Core Insights - The approval of ruxolitinib cream for treating non-segmental vitiligo is expected to drive substantial sales growth, with management projecting revenues of at least CNY 500 million in 2026 and doubling in 2027, reaching a peak of no less than CNY 6 billion within 4-5 years [3][11]. - The cream is positioned to fill a market gap due to the limitations of existing therapies for vitiligo, with a strong demand from patients willing to pay for better efficacy and fewer side effects [4][12]. - The company has initiated pilot applications of the cream in Hainan, with over 7,700 patients already using it before formal approval, indicating strong early adoption [2][10]. Summary by Sections Product Approval and Market Strategy - On January 30, the company’s subsidiary Dermavon received approval from the NMPA for ruxolitinib cream, which is an innovative formulation for treating non-segmental vitiligo in patients aged 12 and above [1][8]. - The company has established exclusive rights for the development and commercialization of the product in several regions, including Mainland China and Southeast Asia [1][8]. Market Potential and Revenue Projections - Management anticipates that the cream will generate revenues of at least CNY 500 million in 2026, with expectations to double in 2027 and reach a peak revenue of no less than CNY 6 billion [3][11]. - The pricing strategy indicates that the listed price will be lower than the previous pilot price of CNY 6,800 per tube [3][11]. Competitive Landscape - Existing treatments for vitiligo have clinical limitations, and ruxolitinib cream is expected to provide a more effective solution, particularly for patients with facial involvement [4][12]. - The cream's efficacy has been supported by real-world data from the Hainan pilot zone, aligning with international clinical study results [4][12]. Future Developments - The company is also focusing on the potential use of ruxolitinib cream for mild-to-moderate atopic dermatitis, with plans to submit a marketing application soon [4][13].

Investment Rating - The report indicates a bullish stance on the energy storage sector, highlighting it as the most favored sector for investment in 2026 due to expected high growth [6][1]. Core Insights - The energy storage industry is anticipated to experience significant growth in 2026, driven by the recent implementation of the capacity tariff policy and adjustments in lithium carbonate prices, which enhance the valuation attractiveness of energy storage companies [6][1]. - The capacity tariff policy, issued by the National Development and Reform Commission and the National Energy Administration, clarifies the pricing mechanism for new-type energy storage, establishing its market position and accelerating nationwide implementation [9][3]. Summary by Sections Weekly Recommendation Logic - The energy storage sector is expected to see high certainty growth in 2026, making it a top investment choice. Recent underperformance is attributed to seasonal demand and rising raw material prices, but valuations have become attractive post-adjustment [6][1]. - The release of the capacity tariff policy and corrections in lithium carbonate prices are key reasons for the positive outlook on the energy storage sector [6][1]. Weekly Recommended Portfolio - Top Picks: Contemporary Amperex Technology Co., Limited (CATL), Sungrow Power Supply Co., Ltd., EVE Energy Co., Ltd., Hyperstrong Energy Storage Technology Co., Ltd. [7][2]. - Sustained Picks: Tsugami Machinery (China) Co., Ltd., Sunwoda Electronic Co., Ltd., Shenzhen Sinexcel Electric Co., Ltd., CALB Group Co., Ltd., Sichuan Fulin Precision Machinery Co., Ltd., Jiangsu Longpan Technology Co., Ltd. [7][2]. Commentary on the Capacity Tariff Policy - The capacity tariff policy categorizes the pricing mechanism for various energy sources, including new-type energy storage, based on local coal-fired power standards and peak-shaving capacity [8][3]. - The policy aims to establish a clear development direction and tariff formulation methodology, which is significant for the national development of the energy storage industry [9][3].

Investment Rating - The report assigns an "Outperform" rating to multiple companies in the discretionary consumption sector, including Nike, Li Ning, Midea Group, JD Group, Haier Smart Home, Gree Electric, Anta Sports, and many others [1]. Core Insights - The discretionary consumption sector has experienced a significant pullback due to the hawkish stance of the Federal Reserve, leading to a decline in global asset prices [4][13]. - The report highlights that the domestic sportswear sector has shown resilience, with a weekly increase of 0.6%, while other sectors such as luxury goods and cosmetics have faced declines [5][15]. - The report notes that various sub-sectors within discretionary consumption have performed differently, with gold and jewelry being the top performers in the recent weeks [4][13]. Summary by Relevant Sections Weekly Performance Review - The report details the weekly performance of various sectors, indicating that domestic sportswear outperformed others with a 0.6% increase, while luxury goods saw a decline of 5.8% [4][13]. - Monthly performance shows gold and jewelry leading with a 14.8% increase, while luxury goods and overseas sportswear faced significant declines [4][13]. Sector Analysis - The domestic sportswear sector's growth is attributed to increased demand for warm clothing due to colder weather and strategic partnerships, such as Anta Sports' acquisition of a stake in PUMA [6][15]. - The credit card sector experienced mixed results, with Mastercard performing well while Visa and American Express faced declines due to varying financial performance [15]. - The retail sector saw a decline of 1.4%, with some companies like China Resources Vanguard performing well due to favorable policies [15]. Valuation Analysis - The report indicates that the expected PE ratios for various sectors in 2025 are below their historical averages, suggesting potential investment opportunities [11][18]. - For instance, the expected PE for the domestic sportswear sector is 13.4 times, which is 70% of its past five-year average [11][18].

Investment Rating - The report maintains an "Outperform" rating for multiple companies in the healthcare sector, including BeiGene, JD Health, WuXi Biologics, and others, while China National Pharmaceutical Group is rated "Neutral" [1]. Core Insights - The Hong Kong healthcare sector experienced a broad-based correction due to capital pressures, with pharmaceutical distribution remaining relatively stable [4][28]. - The Hang Seng Healthcare Index fell by 3.0% this week, underperforming the Hang Seng Index by 5.4 percentage points, but has gained 8.6% year-to-date, outperforming the Hang Seng Index by 1.7 percentage points [14][27]. - The top five gainers in the sector included Leads Biolabs-B (+19.3%), Sihuan Pharmaceutical (+17.9%), and Tigermed (+7.6%), while the bottom five decliners included Medlive Technology (-16.2%) and Laekna-B (-14.1%) [4][29]. Summary by Sections Market Performance - The report indicates that various sub-sectors within the healthcare market have experienced declines, with pharmaceutical distribution down by 0.3%, internet healthcare down by 2.1%, and medical devices down by 5.0% [4][28]. Company Updates - Rongchang Biopharmaceutical announced a revenue forecast of 3.25 billion yuan for 2025, representing a year-on-year increase of 89%, and has turned a profit [11]. - A collaboration agreement was signed between CSPC Pharmaceutical and AstraZeneca, involving a total payment of $18.5 billion for the licensing of GLP-1 long-acting assets [11]. - AstraZeneca plans to invest $15 billion in China by 2030, focusing on expanding drug manufacturing and R&D capabilities [12]. - Kangzheng Pharmaceutical's lebrikizumab cream has been approved for the treatment of non-segmental vitiligo in patients aged 12 and older [12]. Regulatory Developments - The National Health Commission approved a pilot program for internet-based first consultations in Beijing, which is expected to accelerate prescription outflow [13].

孟科含 Kehan Meng 聂照亿 Zhaoyi Nie kh.meng@htisec.com john.zy.nie@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_Title] 研究报告 Research Report 30 Jan 2026 石药集团 CSPC Pharmaceutical Group (1093 HK) 长效多肽产品组合授权阿斯利康，加速全球创新药布局 Long-Acting Peptide Product Portfolio Out-licensed to AZ, Accelerating Global Innovative Drug Deployment [Table_summary] (Please see APPENDIX 1 for English summary) 事件 石药创新（新诺威 300765.SZ，石药集团的控股子公司）的控股子公司巨石生物及石药集团、中奇制药（石药集团 的全资控股子公司）共同与阿斯利康签署《战略合作与授权协议》，将与阿斯利康在创新多肽分子发现和长效递 送产品的开发领域开展全面战略合作。 ...

Investment Rating - The report maintains an "Outperform" rating for Sands China [2][16]. Core Insights - The company achieved net revenue of USD 2.058 billion in Q4 2025, representing a year-over-year increase of 16.2%. Adjusted property EBITDA reached USD 608 million, up 6.5% year-over-year, with an adjusted property EBITDA margin of 29.5% [4][12][15]. - The performance of the company's properties varied, with The Venetian and Plaza showing net revenue increases both year-over-year and quarter-over-quarter, while The Parisian and Sands underperformed [13][14]. - The company's gaming gross revenue increased significantly to USD 2.02 billion, up 23.1% year-over-year, driven by growth in VIP and premium mass segments [5][14]. - The adjusted EBITDA margin declined to 29.5%, down 2.7 percentage points year-over-year, primarily due to a shift in business structure and rising operating costs [6][15]. - The company's market share improved to 24.4% in Q3 2025, up from 23.7% in Q3 2024, indicating a positive trend in competitive positioning [7]. Financial Projections - The company is expected to generate net revenues of USD 7.937 billion and USD 8.363 billion for FY 2026 and FY 2027, respectively, with growth rates of 6.2% and 5.4% [16]. - Gaming gross revenue is projected to be USD 7.652 billion and USD 8.082 billion for FY 2026 and FY 2027, reflecting year-over-year growth of 6.6% and 5.6% [16]. - Adjusted property EBITDA is forecasted to reach USD 2.483 billion and USD 2.643 billion for FY 2026 and FY 2027, with corresponding margins of 31.3% and 31.6% [16].

Investment Rating - The report maintains an "Outperform" rating for Zai Lab with a target price of HKD 35.25, while the current price is HKD 13.82 [2][10]. Core Insights - Zai Lab is expected to achieve product net revenue of USD 465 million in FY25, representing a year-on-year growth of 16.5%. The core product efgartigimod is projected to generate USD 97.96 million, with a gross profit margin of 61.0% [3][16]. - The management has reaffirmed a dual-engine strategy focusing on introducing high-quality overseas products for commercialization in China and leveraging a cross-border R&D platform for efficient global market development [4][17]. - Despite a downward revision in revenue guidance for 2025 and a delay in profitability targets, the company has a robust portfolio with eight products approved in China and several differentiated global assets in its pipeline [4][17]. Financial Performance - Revenue forecasts for FY25, FY26, and FY27 have been adjusted to USD 465 million, USD 501 million, and USD 717 million, respectively. Net loss forecasts for the same periods are revised to USD 180 million, USD 159 million, and USD 55 million [10][19]. - R&D expenses are expected to be USD 205 million, a decrease of 12.8% year-on-year, while SG&A expenses are projected at USD 284 million, down 5.0% [3][16]. Clinical Development Pipeline - Zocilurtatug (DLL3 ADC) is set to initiate three registrational clinical trials by the end of 2026, targeting small cell lung cancer and neuroendocrine carcinoma [5][21]. - Several early-stage products, including ZL-1503, ZL-6201, ZL-1222, and ZL-1311, are expected to contribute to long-term global value creation [6][9][21].

Investment Rating - The report maintains an "Outperform" rating for Cirrus Aircraft [2][9]. Core Insights - Cirrus Aircraft's strong competitive advantage is attributed to its extensive network of service and training sites, combined with user-friendly products. The company has approximately 260 service locations globally, including 193 authorized service centers in major U.S. regions [3][10]. - The company is projected to deliver around 800 aircraft in 2025, with an optimistic outlook for new orders, expecting approximately 600 new orders for the year. The SR2X series is expected to see a 10% year-on-year increase in deliveries [4][11]. - The average selling price for the SR2X series is anticipated to rise to approximately US$1.19 million, while the Vision Jet's average price is expected to increase to US$3.45 million, contributing to improved profit margins [4][11]. Financial Projections - Revenue projections for Cirrus Aircraft are set at US$1.394 billion for 2025, US$1.674 billion for 2026, and US$1.951 billion for 2027, with corresponding net profits of US$159 million, US$183 million, and US$204 million [5][13]. - The overall gross profit margin is expected to increase by 0.9 percentage points year-on-year, while the net profit margin is projected to rise by 1.1 percentage points [4][11]. Valuation - The target price for Cirrus Aircraft has been raised to HK$70.20, based on a PE ratio of 18x applied to the expected EPS for 2026 [5][13].

研究报告 Research Report 28 Jan 2026 安踏体育 ANTA SPORTS (2020 HK) 战略性收购 Puma 29.06%股权，继续推进单聚焦+多品牌+全球化战略 Strategic Acquisition of a 29.06% Stake in Puma to Further Advance the Strategy of Single Focus, Multi-Brand and Globalization [Table_yemei 观点聚焦 1] Investment Focus [Table_Info] 维持优于大市 Maintain OUTPERFORM 评级 优于大市 OUTPERFORM 现价 HK$77.90 目标价 HK$91.40 HTI ESG 0.7-1.6-3.5 E-S-G: 0-5, (Please refer to the Appendix for ESG comments) 市值 HK$217.86bn / US$27.94bn 日交易额 (3 个月均值) US$93.59mn 发行股票数目 2,797mn 自由流通股 (%) 47% 1 年 ...